An international group of scientists has called for a global moratorium on gene-edited babies; proposed guidance would limit the sale of flavored e-cigarettes; and the Senate has invited executives from 5 pharmacy benefit managers (PBMs) to testify at a hearing on drug prices.
Months after the controversial births of the world's first gene-edited babies, a group of 18 researchers from around the globe are calling for a world-wide moratorium on editing DNA in human sperm, eggs, and embryos, reported The Wall Street Journal. The researchers, who include some inventors of CRISPR, said that a moratorium would prevent irresponsible use of the technology before it causes irreversible changes.As part of the FDA’s ongoing effort to combat teen vaping, Commissioner Scott Gottlieb, MD, introduced proposed guidance that would limit the sale of flavored e-cigarettes to vape shops that bar sales to minors. The changes would not apply to menthol, mint, and tobacco flavors. According to The Hill, the proposal would likely ban sales of e-cigarettes at gas stations and convenience stores.The Senate Finance Committee has invited 5 executives from PBMs to its third drug pricing hearing on April 3. According to Reuters, Committee Chair Senator Chuck Grassley, R-Iowa, and Senator Ron Wyden, D-Oregon, invited executives from UnitedHealth Group’s OptumRx Cigna, Humana, CVS Caremark, and Prime Therapeutics to testify on rising prescription drug prices.
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Team Coordination, Data Sharing Help Prioritize Value in Cardio-Renal-Metabolic Care
September 12th 2025Cardiologists, nephrologists, and payers met in Scottsdale, Arizona, on August 26, 2025, to share insights on how team members can work together, empowered by data, to achieve value-based management of cardio-renal-metabolic syndrome.
Read More